Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04871139 · ClinicalTrials.gov registry record · NA

An Imaging Technology, Contrast-Enhanced Mammography, in Predicting Breast Cancer

A NA study of Breast Carcinoma, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
NA
Development phase
100
Enrollment target
1
Study location

NCT04871139: Recruiting NA study of Breast Carcinoma, sponsored by M.D. Anderson Cancer Center.

NCT04871139 is a NA study of Breast Carcinoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 100 participants, below the 770-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04871139, a NA study of Breast Carcinoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
NA
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

This clinical trial examines a new imaging technology, contrast-enhanced mammography, in predicting breast cancer. Contrast-enhanced mammography is similar to standard mammography, but it includes an intravenous (by vein) injection of iodine-based contrast, which makes tissue and blood vessels more visible in scans. Contrast-enhanced mammography may work better in detecting cancer in the breast that is not seen on other imaging tests and may help doctors find the most suspicious areas of the breast to biopsy, which could increase the chances of finding breast cancer.

Primary Outcome

Will examine the accuracy of CEM compared to full field digital mammography (FFDM) in predicting invasive malignancy or ductal carcinoma in situ (DCIS) in patients with mammographic architectural distortion (MAD)s.

Conditions Studied

Interventions

  • PROCEDURE Biopsy
  • OTHER Questionnaire Administration
  • PROCEDURE Contrast-Enhanced Mammography
  • OTHER Radioactive Iodine

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2021-04-08
Est. Completion 2026-03-01
Phase NA
M.D. Anderson Cancer Center

2,692 total trials

What NCT04871139 shows while recruiting

NCT04871139 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 770-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (87% lower).

The record links to 1 condition, with Breast Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Biopsy is the first listed.

NCT04871139 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT04871139 about?

NCT04871139 is a clinical study titled "An Imaging Technology, Contrast-Enhanced Mammography, in Predicting Breast Cancer". This clinical trial examines a new imaging technology, contrast-enhanced mammography, in predicting breast cancer. Contrast-enhanced mammography is similar to standard mammography, but it includes an intravenous (by vein) injection of iodine-based contrast, which makes tissue and blood vessels more ...

What is the current status of trial NCT04871139?

This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2021-04-08. Estimated completion is 2026-03-01.

What conditions does trial NCT04871139 study?

This clinical trial studies the following conditions: Breast Carcinoma.

What interventions are being tested in trial NCT04871139?

The interventions under investigation include: Biopsy (PROCEDURE), Questionnaire Administration (OTHER), Contrast-Enhanced Mammography (PROCEDURE), Radioactive Iodine (OTHER).

Who is sponsoring clinical trial NCT04871139?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04871139 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04871139's enrollment target sits among peer trials

100 59th of 106 higher than 45 of 106 other Breast Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04871139, the US trial registry maintained by the National Library of Medicine. NCT04871139 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.